Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +2.26%34 Forward Dividend Yield % is 0.00% as of Aug. 13, 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 149 Biotechnology companies, Solid Biosciences ranks worse than 671140.27% on this metric.
As of today (2026-08-13), the Forward Annual Dividend Yield of Solid Biosciences is 0.00%.
As of today (2026-08-13), the Trailing Annual Dividend Yield of Solid Biosciences is 0.00%.
SLDB's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.3 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Solid Biosciences Forward Dividend Yield % Related Terms
SLDB vs MNPR, DSGN, CLYM: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Solid Biosciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Solid Biosciences (SLDB) has a Forward Dividend Yield % of 0.00% as of Aug. 13, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Solid Biosciences and its competitors. According to the industry distribution chart, Solid Biosciences ranks #999999 out of 149 companies in the Biotechnology industry.
Is Solid Biosciences' Forward Dividend Yield % too high?
Solid Biosciences' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Solid Biosciences ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' Forward Dividend Yield % compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Solid Biosciences in the lower half of its industry. The industry median Forward Dividend Yield % is 1.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.30, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Solid Biosciences and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current Forward Dividend Yield % is 0.00% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
